This paper explores the dynamic nature of sudden cardiac death (SCD) risk, distinguishing between transient and persistent periods of vulnerability in patients with recent myocardial infarction, newly diagnosed cardiomyopathy, or heart failure. It emphasizes that implantable cardioverter-defibrillators (ICDs) may be inappropriate during early, potentially reversible phases, and highlights the role of wearable cardioverter-defibrillators (WCDs) in providing temporary protection while patients undergo guideline-directed therapy optimization and cardiac recovery. By integrating WCD use into clinical workflows and accelerating therapy initiation, health systems can reduce SCD burden and improve patient outcomes.
Tina Baykaner, MD, FHRS-- Reseach: NIH
-- Honoraria/Speaking/Consulting: Medtronic, Pacemate, Volta Medical, iRhythm
Krishna Pundi, MD
--Honoraria/Speaking/Consulting: Evidently, iRhythm Technologies, AltaThera Pharmaceuticals
--Research: American College of Cardiology Foundation
Peter Noseworthy, MD, FHRS
--Research: NIH, National Institute on Aging, Agency for Healthcare Research and Quality, USFDA, AHA, Medtronic
--Honoraria/Speaking/Consulting: Optum
--Royalty: AliveCor
Nino Isakadze, MD, MHS
--Research: Apple, Itamar Medical
--Honoraria/Speaking/Consulting: Boston Scientific
Gerilynn M. Schott, MSN, ACNP
--Nothing to disclose